Harbin Gloria Pharmaceuticals Co., Ltd. (002437) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harbin Gloria Pharmaceuticals Co., Ltd.

Why is Harbin Gloria Pharmaceuticals Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 5.00%

The company has been able to generate a Return on Capital Employed (avg) of 5.00% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -7.25% and Operating profit at 28.59% over the last 5 years

With a growth in Net Profit of 47.42%, the company declared Very Positive results in Sep 25

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at CNY 455.92 MM
ROCE(HY) Highest at 14.47%
DEBT-EQUITY RATIO (HY) Lowest at -35.12 %

With ROE of 11.86%, it has a fair valuation with a 3.39 Price to Book Value

Over the past year, while the stock has generated a return of 29.80%, its profits have risen by 1.3% ; the PEG ratio of the company is 4.1

Market Beating performance in long term as well as near term

Along with generating 29.80% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Harbin Gloria Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harbin Gloria Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Harbin Gloria Pharmaceuticals Co., Ltd.

27.53%

1.73

41.63%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-7.25%

EBIT Growth (5y)

28.59%

EBIT to Interest (avg)

9.96

Debt to EBITDA (avg)

0.31

Net Debt to Equity (avg)

-0.27

Sales to Capital Employed (avg)

1.13

Tax Ratio

12.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.00%

ROE (avg)

4.75%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.39

EV to EBIT

28.64

EV to EBITDA

20.41

EV to Capital Employed

4.19

EV to Sales

2.81

PEG Ratio

4.05

Dividend Yield

ROCE (Latest)

14.63%

ROE (Latest)

11.86%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 455.92 MM

ROCE(HY)

Highest at 14.47%

DEBT-EQUITY RATIO (HY)

Lowest at -35.12 %

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

NET PROFIT(Q)

Highest at CNY 81.87 MM

PRE-TAX PROFIT(Q)

Highest at CNY 89.06 MM

EPS(Q)

Highest at CNY 0.05

-5What is not working for the Company

NET SALES(HY)

At CNY 1,113.74 MM has Grown at -11.91%

RAW MATERIAL COST(Y)

Grown by 12.7% (YoY

Here's what is working for Harbin Gloria Pharmaceuticals Co., Ltd.

Net Profit

Highest at CNY 81.87 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -35.12 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Cash Flow

Highest at CNY 455.92 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

Highest at CNY 89.06 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

EPS

Highest at CNY 0.05

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Here's what is not working for Harbin Gloria Pharmaceuticals Co., Ltd.

Net Sales

At CNY 1,113.74 MM has Grown at -11.91%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Raw Material Cost

Grown by 12.7% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales